Already a member? Click here to login.
Already a member? Click here to login.
Home > Uncategorized > Risk of Diabetic Ketoacidosis during Treatment with Sodium Glucose Co-transporter 2 Inhibitors
Home > Uncategorized > Risk of Diabetic Ketoacidosis during Treatment with Sodium Glucose Co-transporter 2 Inhibitors ADEA has been advised by a letter on behalf of AstraZeneca, Boehringer Ingelheim and Janssen-Cilag of new safety information for prescription medicines containing canagliflozin, dapagliflozin, or empagliflozin. These are inhibitors of sodium glucose co-transporter 2 (SGLT2) approved as oral antihyperglycemic agents for the treatment of patients with type 2 diabetes.
The attached letter outlines the details of this new safety information and has been shared with the TGA and a number of healthcare professionals including GPs, endocrinologists, renal physicians.
ADEA has been advised by a letter on behalf of AstraZeneca, Boehringer Ingelheim and Janssen-Cilag of new safety information for prescription medicines containing canagliflozin, dapagliflozin, or empagliflozin. These are inhibitors of sodium glucose co-transporter 2 (SGLT2) approved as oral antihyperglycemic agents for the treatment of patients with type 2 diabetes.
The attached letter outlines the details of this new safety information and has been shared with the TGA and a number of healthcare professionals including GPs, endocrinologists, renal physicians.